Retargeting IL-2 Signaling to NKG2D-Expressing Tumor-Infiltrating Leukocytes Improves Adoptive Transfer Immunotherapy
Open Access
- 21 June 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 207 (1) , 333-343
Abstract
Ex vivo expansion followed by reinfusion of tumor-infiltrating leukocytes (TILs) has been used successfully for the treatment of multiple malignancies. Most protocols rely on the use of the cytokine IL-2 to expand TILs prior to reinfusion. In addition, TIL administration relies on systemic administration of IL-2 after reinfusion to support transferred cell survival. The use of IL-2, however, can be problematic because of its preferential expansion of regulatory T and myeloid cells as well as its systemic side effects. In this study, we describe the use of a novel IL-2 mutant retargeted to NKG2D rather than the high-affinity IL-2R for TIL-mediated immunotherapy in a murine model of malignant melanoma. We demonstrate that the NKG2D-retargeted IL-2 (called OMCPmutIL-2) preferentially expands TIL-resident CTLs, such as CD8+ T cells, NK cells, and γδT cells, whereas wild-type IL-2 provides a growth advantage for CD4+Foxp3+ T cells as well as myeloid cells. OMCPmutIL-2–expanded CTLs express higher levels of tumor-homing receptors, such as LFA-1, CD49a, and CXCR3, which correlate with TIL localization to the tumor bed after i.v. injection. Consistent with this, OMCPmutIL-2–expanded TILs provided superior tumor control compared with those expanded in wild-type IL-2. Our data demonstrate that adoptive transfer immunotherapy can be improved by rational retargeting of cytokine signaling to NKG2D-expressing CTLs rather than indiscriminate expansion of all TILs.Keywords
Funding Information
- Foundation for the National Institutes of Health (R41 CA224520-01A1)
- Foundation for the National Institutes of Health (RO1AI145108-01)
- U.S. Department of Veterans Affairs (IO1 IBX0104588A)
- Foundation for the National Institutes of Health (P01 AI116501)
This publication has 58 references indexed in Scilit:
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’Nature, 2012
- Immunotype and Immunohistologic Characteristics of Tumor-Infiltrating Immune Cells Are Associated with Clinical Outcome in Metastatic MelanomaCancer Research, 2012
- Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumoursBritish Journal of Cancer, 2011
- CD4 + CD25 + regulatory T cells control CD8 + T-cell effector differentiation by modulating IL-2 homeostasisProceedings of the National Academy of Sciences, 2011
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and ImmunityImmunity, 2010
- Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cellsProceedings of the National Academy of Sciences, 2010
- Depletion of tumor‐induced Treg prior to reconstitution rescues enhanced priming of tumor‐specific, therapeutic effector T cells in lymphopenic hostsEuropean Journal of Immunology, 2009
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative RegimensJournal of Clinical Oncology, 2008
- Zoonotic orthopoxviruses encode a high-affinity antagonist of NKG2DJournal of Experimental Medicine, 2007
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988